BioSpace News Archive

Stealth BioTherapeutics Corp (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discovery, development, and commercialization of novel therapies for diseases involving mitochondrial dysfunction, today announced that the company will have a poster presentation with a live discussion at the upcoming 2021 Association for Research in Vision and Ophthalmology (ARVO) Virtual Annual Meeting

Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today announced it will participate in the 7th Annual Truist Securities Life Sciences Summit

MorphoSys AG, a commercial-stage biopharmaceutical company and a leader in antibody, protein and peptide technologies, will publish its results for the first quarter of 2021 on May 5, 2021 at 10:00pm CEST.

Alexion Pharmaceuticals, Inc. announced that the Company will report its financial results for the first quarter ended March 31, 2021 before the US financial markets open on April 30, 2021, rather than on May 3, 2021 as previously announced.

Nortech Systems Incorporated (Nasdaq: NSYS) (the “Company”), a leading provider of engineering and manufacturing solutions for complex electromedical and electromechanical products serving the medical, aerospace & defense and industrial markets, announced today it will release its fiscal 2021 first quarter financial results for the period ended March 31, 2021 before the markets open on Thursday, May 13.

MiMedx Group, Inc., an industry leader in utilizing amniotic tissue as a platform for regenerative medicine, announced the filing of its first quarter 2021 Form 10-Q for the period ended March 31, 2021.

Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that the New England Journal of Medicine (NEJM) has published the results of the global Phase 3 clinical program of vadadustat for the treatment of anemia due to chronic kidney disease (CKD) in adult patients on dialysis

Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, today announced it has signed an agreement to acquire exclusive U.S. commercialization rights to Simbrinza®(brinzolamide/brimonidine tartrate ophthalmic suspension) 1%/0.2% from Novartis.

A new peer-reviewed study accepted in the Journal of the American College of Cardiology: Cardiovascular Imaging validated Myocardial Solutions (“MSI”) technologies MyoStrain and MyoStress in a new stress testing protocol utilizing a hyperventilation breath-hold (HVBH) maneuver to accurately detect myocardial ischemia

Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases, today announced the pricing of an underwritten public offering of 10,000,000 shares of its common stock at a public offering price of $12.50 per share